FDG-PET [fluorodeoxyglucose-positron emission tomography]-Stratified R-DICEP [rituximab-dose-intensive cyclophosphamide + etoposide + cisplatin] and R-BEAM [rituximab-carmustine + etoposide + melphalan]/ASCT [autologous stem cell transplant] For Diffuse Large B-Cell Lymphoma.

Trial Profile

FDG-PET [fluorodeoxyglucose-positron emission tomography]-Stratified R-DICEP [rituximab-dose-intensive cyclophosphamide + etoposide + cisplatin] and R-BEAM [rituximab-carmustine + etoposide + melphalan]/ASCT [autologous stem cell transplant] For Diffuse Large B-Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Melphalan; Prednisolone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms PET-Chop
  • Most Recent Events

    • 27 Oct 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 06 Dec 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 06 Dec 2011 Roche added as trial affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top